Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956640 · ClinicalTrials.gov registry record · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT04956640: Recruiting Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Eli Lilly and Company.
NCT04956640 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 540 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04956640, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Primary Outcome
Measured by the number of patients with dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG LY3537982
Study Locations (20)
New York
- NYU Langone Health- Long Island - Mineola
- NYU Langone - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
- Novant Health Cancer Institute - Elizabeth - Charlotte
- Novant Health Cancer Institute - Forsyth - Winston-Salem
California
- USC Norris Cancer Hospital - Los Angeles
- Chao Family Comprehensive Cancer Ctr. - Orange
Florida
- AdventHealth Orlando - Orlando
- Florida Cancer Specialists - Sarasota
Indiana
- Indiana Univ Melvin & Bren Simon Cancer Center - Indianapolis
- Community Health Network - Indianapolis
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT04956640 shows while recruiting
NCT04956640 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (69% higher).
The record links to 6 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04956640 names 20 study sites across 12 states, led by New York, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT04956640 about?
NCT04956640 is a clinical study titled "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)". The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had ca...
What is the current status of trial NCT04956640?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 540 participants. The study started on 2021-07-19. Estimated completion is 2027-04.
What conditions does trial NCT04956640 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms.
What interventions are being tested in trial NCT04956640?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), LY3537982 (DRUG).
Who is sponsoring clinical trial NCT04956640?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04956640 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04956640's enrollment target sits among peer trials
540 27th of 130 higher than 104 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- NCT05588245 · 540 participants · NA
Trial of Community-based Patient Navigation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI